Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

Study Overview
=================
Brief Summary
-----------------
Testosterone(T) has known effects on many organ systems, although many of its metabolic actions are unrevealed. T is an anabolic hormone stimulating protein synthesis but this effect has barely been investigated in controlled studies. It also has lipolytic actions influencing body composition, but little is known of its regional impact on fat tissue. T affects insulin sensitivity. There is an increased incidence of hypogonadism in type 2 diabetes, and among patients with hypogonadism there is an increased incidence of type 2 diabetes. The actions of testosterone on glucose metabolism are unknown. The purpose of this study is therefore to: Investigate the lipolytic effect of testosterone on muscle and fat tissue. To gain insight in the intracellular mechanisms of testosterone on lipolysis and investigate possible regional differences in lipolysis and changes in body composition. Finally to investigate the effect of short term experimental hypogonadism and acute testosterone substitution on cytokines, insulin sensitivity and protein metabolism. The trial is a randomised double blinded cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young men will receive GnRH treatment over a 3 month period and examined on 4 occasions with various degrees of T substitution and placebo . The examinations take place at the Research Lab within the Medical Department M. The investigations are deemed relevant to the understanding of the interrelationship between male hypogonadism and type 2 diabetes. The hypothesis is that T has beneficial effects on carbohydrate, fat and protein metabolism. The generated knowledge would therefore hopefully improve prophylaxis, screening and early treatment of both group of patients.

Official Title
-----------------
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

Conditions
-----------------
Hypogonadism

Intervention / Treatment
-----------------
* Drug: Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male, age 20-35 Normal biochemical screen and ECG Exclusion Criteria: Heart disease BMI>25 Diabetes Antecedent or present cancer Vascular disease Antecedent or present hormone treatment Medical treatment with known effects on fat metabolism Big X-ray examinations equivalent to, or more than a chest x-ray and all kinds of CT scans until 6 month before the start of the study and during the study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo<br>* The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention. The four days will include treatment on the examination day, Day 1 with: Placebo (hypogonadism after leuprorelide injection) Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection). Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection). No treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Testosterone influence on Insulin Sensitivity, Lipolysis and protein metabolism |  | 4-6 month pr patient | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Testosterone influence on Body composition by DEXA scan, Energy expenditure by indirect Calorimetry and VO2 max test |  | 4-6 month pr patient | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute, testosterone, experimental, hypogonadism, lipolysis, insulin sensitivity, protein, metabolism, Experimental hypogonadism, Testosterone substitution